XPENG
XPENG (the “Company”, NYSE: XPEV and HKEX: 9868), a leading smart mobility and technology company, today kicks off customer reservations of its third and latest production model on the market, the XPENG P5 smart EV sedan, simultaneously in Denmark, the Netherlands, Norway and Sweden. The move marks a major milestone in its European expansion plans.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220310005596/en/
XPENG today is also opening its first XPENG Experience Store in the Netherlands, its second branded showroom in Europe, following the opening of the Stockholm XPENG Experience Store in Sweden last month.
The XPENG P5 is the Company’s first model to be made available simultaneously in four European markets. The customer reservation process is fully-digitized, and accessible immediately in each of these four markets, both via the XPENG official websites in each country, and the XPENG mobile APP launched earlier this week.
“The XPENG P5’s arrival in four key European markets is a new demonstration of our commitment to Europe,” said Leon He, Vice President of XPENG. “Each new XPENG model achieves a new level of technology sophistication. The P5 brings a host of differentiated features to a new customer base in Europe, a market where we are building ourselves as a long-term player,” said Mr. He.
The XPENG P5 – Intelligence that moves you
The XPENG P5, a mid-size family sedan, is equipped with version 2.5 of XPENG’s in-house developed Advanced Driver Assistance System (XPILOT), and its intelligent in-car operating system - Xmart OS. The P5 combines the advanced level of driver assistance with superior passenger comfort and convenience. Through firmware over-the-air (OTA) upgrades, the P5 will bring new features and optimized functions to customers on a continuous basis.
The sleek aerodynamic profile of the P5 with a large panoramic canopy glass sunroof, neat fastback and unobtrusive ducktail gives it a driving range of 465 km WLTP, powered by a battery of 66 kWh capacity.
The Xmart OS provides comprehensive cockpit and interior function management, with a 12.3-inch LCD dashboard, a 15.6-inch FHD high resolution (1920 * 1080) large center display, in-car voice control capable of distinguishing between driver and passenger positions, and a library of in-car Apps to assist, inform, and entertain driver and passengers.
This intelligent cockpit management is integrated into the stylish interior fittings, with heated leatherette seats, the Xfreebreath intelligent air purification system and advanced surround sound system. Many vehicle functions can also be accessed via mobile phone remote control.
For added convenience, the P5 incorporates 26 storage compartments and a 450L large trunk, plus an additional 70L compartment underneath.
XPENG experience store starts operation in the Netherlands
Concurrently, XPENG is also opening its first experience store in the Westfield Mall of the Netherlands in Leidschendam, conveniently close to major conurbations such as Rotterdam and The Hague. As well as the XPENG P5, the XPENG smart sports sedan P7, and the prototype of its flying vehicle XPENG X2 are also on display in the Westfield Mall experience store, demonstrating the brand’s vision of future mobility and its spirit of exploration.
Customers can make online reservations for XPENG P5 from today. The test drive will be available in April 2022.
Two additional stores in the Netherlands will open later this year in collaboration with XPENG's local partner Emil Frey, and the Company plans to open more stores in major cities across the Netherlands over the next few years.
XPENG P5 Specs
Dimension |
|
Length x Width x Height (mm) |
4808mm / 1840mm / 1520mm |
Wheelbase (mm) |
2768mm |
Seats |
5 |
Curb Weight (kg) |
1715Kg |
Cargo Space |
520 L |
Performance |
|
Type of Drive |
Front-wheel drive |
Battery Capacity (kWh) |
66 kWh |
WLTP Driving Range (km) |
465 Km |
XPILOT 2.5 (ADAS) |
|
High-definition Millimeter Wave Radar |
5 |
Ultrasonic Wave Sensors |
12 |
Autonomous Driving Surround View Camera |
4 |
Autonomous Driving High Perception Camera |
9 |
XPILOT Safety |
● |
XPILOT Driving |
● |
XPILOT Parking |
● |
Xmart OS In-car Intelligent System |
|
15.6" Central Touch Screen Display |
● |
12.3" HD Liquid Crystal Intelligent Instrument Panel |
● |
Mobile App Remote Control |
● |
"Hey XPENG" Voice Assistant |
● |
Firmware over-the-air software updates |
● |
Exterior |
|
Lightsaber 3.0 LED Lights |
● |
Lightsaber 3.0 LED DRL |
● |
Panoramic Sunroof |
● |
215/55R18 Michelin Tyre |
● |
About XPENG
XPENG is a leading smart mobility company founded with a mission to explore and drive smart EV transformation with technology, shaping the mobility experience of the future. In order to optimize its customers’ mobility experience, XPENG develops in-house its full-stack autonomous driving technology and in-car intelligent operating system, as well as core vehicle systems including powertrain and the electrical/electronic architecture. XPENG is headquartered in Guangzhou, China, with main offices in Beijing, Shanghai, Silicon Valley and San Diego. In 2021, XPENG established its European headquarters in the Netherlands, and is expanding its presence in Sweden, Norway and Denmark. XPENG's smart EVs are manufactured at its fully-owned plant in Zhaoqing, Guangdong Province, China. For more information, please visit: www.heyxpeng.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220310005596/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press release
BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancerFDA Fast Track Designation reflects the potential of BGB-B2033 in an area of high unmet need BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currentl
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom